Drugs / BMX-010
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02457858 | Aug 2014 → Aug 2016 | type 1 diabetes mellitus | University of Alberta | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03752242 | Jan 2019 → Aug 2020 | acne | BioMimetix JV, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03756389 | Jan 2018 → Sep 2024 | rosacea | BioMimetix JV, LLC | Suspended | No outcome recorded |
| Phase 2 | NCT03381625 | Jan 2018 → Jul 2021 | atopic eczema, psoriasis | BioMimetix JV, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05491447 Comparator | Jan → Dec 2023 | atopic eczema | BioMimetix JV, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMX-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05491447 ↗ |
| Known as | AEOL-10113 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297709 ↗ |
| Route | Topical | “In this trial BMX-010 will be topically applied twice daily for up to 28 days.” NCT03381625 ↗ |